Vanda Pharmaceuticals (VNDA) Total Non-Current Liabilities (2011 - 2026)

Vanda Pharmaceuticals (VNDA) has 15 years of Total Non-Current Liabilities data on file, last reported at $142.6 million in Q1 2026.

• For the quarter ending Q1 2026, Total Non-Current Liabilities rose 28.18% year-over-year to $142.6 million; the trailing twelve-month figure through Mar 2026 stood at $142.6 million (up 28.18% YoY), and the FY2025 full-year result was $152.2 million, up 40.86% from the prior year.
• Total Non-Current Liabilities fell to $142.6 million in Q1 2026, from $152.2 million in the prior quarter.
• In the past five years, Total Non-Current Liabilities ranged from a high of $152.2 million in Q4 2025 to a low of $92.3 million in Q3 2023.
• A 5-year average of $108.6 million and a median of $100.4 million in 2022 frame the typical range for Total Non-Current Liabilities.
• Across the five-year window, Total Non-Current Liabilities declined 9.08% in 2023 and soared 40.86% in 2025, its largest moves.
• Tracing VNDA's Total Non-Current Liabilities over 5 years: stood at $100.2 million in 2022, then decreased by 5.53% to $94.7 million in 2023, then rose by 14.12% to $108.1 million in 2024, then surged by 40.86% to $152.2 million in 2025, then decreased by 6.3% to $142.6 million in 2026.
• Business Quant data shows VNDA's Total Non-Current Liabilities at $142.6 million in Q1 2026, $152.2 million in Q4 2025, and $124.1 million in Q3 2025.